• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

New Study Shows Mushrooms Can Reverse Alcohol Brain Damage

Jason Najum by Jason Najum
December 1, 2021
in Science
Reading Time: 2 mins read
A A

A new study released last week shows that psilocybin, the psychoactive ingredient in magic mushrooms, can change the part of the brain that controls alcoholism or alcohol cravings.

Published in the journal Science Advances, this new study gives supporting evidence to the anecdotal accounts and increasing amounts of scientific data showing that psychedelics can be a powerful anti-addiction tool.

This research, conducted by a group of over a dozen researchers from across the globe, focuses on the neurobiological level, more specifically, a “mGluR2” glutamate receptor in the brain-damaged by alcohol use.

“We used an established model of alcohol dependence, in which rats receive chronic intermittent exposure (CIE) to alcohol vapor. This leads to intoxication levels similar to those seen in clinical alcohol addiction and induces long-lasting behavioral and pronounced molecular changes in the brain. Alcohol-dependent rats in this model show persistent escalation of alcohol self-administration, increased motivation to obtain alcohol, and increased relapse-like behavior (32–34). Rats were made alcohol-dependent by CIE for 7 weeks.”

[bsa_pro_ad_space id=2]
ADVERTISEMENT

So they turned rats into alcoholics, poor little fellas. The researchers monitored changes to the mice’s brain at the molecular level as well as their behavior. Being hooked on the bottle actually changed the mice’s brain (particularly in the mGluR2 glutamate receptor), making them chronically want more alcohol and also caused damage to other higher-level functions.

Continue on your trip...

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

Secure Lasix Purchase Online

what-are-magic-mushrooms?-exploring-the-science-&-secrets-of-psilocybin

The drunken, brain-damaged rodents were then divided into groups and given psilocybin treatments (low dose, high dose, and a control group). And the results were impressive.

In both psilocybin groups the mGluR2 levels were regenerated after treatment, and the addictive behavior was severely reduced: the magic mushroom group relapsed back to the alcohol approx 45 percent less than the non-psilocybin group.

This also identified potential biomarkers that could be used for treating future patients with these conditions.

In all, despite being a non-human study, these were very positive results that will likely help in future addiction and alcoholism studies (like the ones being done by Mydecine and Johns Hopkins).

See the full study here.

 

Interested in more news about groundbreaking studies? See Mydecine Announces New Clinical Trial for Smoking Cessation

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
Cybin Gets FDA Approval For New Phase 2 Trial

Cybin Gets FDA Approval For New Phase 2 Trial

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.